Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
2001 2
2002 13
2003 25
2004 28
2005 29
2006 29
2007 32
2008 38
2009 52
2010 65
2011 103
2012 105
2013 91
2014 92
2015 111
2016 97
2017 114
2018 115
2019 118
2020 119
2021 116
2022 103
2023 58

Text availability

Article attribute

Article type

Publication date

Search Results

1,442 results

Results by year

Filters applied: . Clear all
Page 1
Design of protein-binding proteins from the target structure alone.
Cao L, Coventry B, Goreshnik I, Huang B, Sheffler W, Park JS, Jude KM, Marković I, Kadam RU, Verschueren KHG, Verstraete K, Walsh STR, Bennett N, Phal A, Yang A, Kozodoy L, DeWitt M, Picton L, Miller L, Strauch EM, DeBouver ND, Pires A, Bera AK, Halabiya S, Hammerson B, Yang W, Bernard S, Stewart L, Wilson IA, Ruohola-Baker H, Schlessinger J, Lee S, Savvides SN, Garcia KC, Baker D. Cao L, et al. Among authors: park js. Nature. 2022 May;605(7910):551-560. doi: 10.1038/s41586-022-04654-9. Epub 2022 Mar 24. Nature. 2022. PMID: 35332283 Free PMC article.
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.
Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, Lee S, Park SH, Park JO, Park YS, Lim HY, Lee H, Choi M, Talasaz A, Kang PS, Cheng J, Loboda A, Lee J, Kang WK. Kim ST, et al. Among authors: park jo. Nat Med. 2018 Sep;24(9):1449-1458. doi: 10.1038/s41591-018-0101-z. Epub 2018 Jul 16. Nat Med. 2018. PMID: 30013197 Clinical Trial.
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.
Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT, Tran B, Kelley RK, Park JO, Javle M, He Y, Benhadji KA, Goyal L. Meric-Bernstam F, et al. Among authors: park jo. Cancer Discov. 2022 Feb;12(2):402-415. doi: 10.1158/2159-8290.CD-21-0697. Epub 2021 Sep 22. Cancer Discov. 2022. PMID: 34551969 Free PMC article. Clinical Trial.
The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review.
Tizaoui K, Yang JW, Lee KH, Kim JH, Kim M, Yoon S, Jung Y, Park JB, An K, Choi H, Song D, Jung H, Ahn S, Yuh T, Choi HM, Ahn JH, Kim Y, Jee S, Lee H, Jin S, Kang JG, Koo B, Lee JY, Min KM, Yoo W, Rhyu HJ, Yoon Y, Lee MH, Kim SE, Hwang J, Koyanagi A, Jacob L, Park S, Shin JI, Smith L. Tizaoui K, et al. Among authors: park jb. Int J Biol Sci. 2022 May 21;18(9):3731-3746. doi: 10.7150/ijbs.67587. eCollection 2022. Int J Biol Sci. 2022. PMID: 35813465 Free PMC article. Review.
Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.
Park JS, Gazzaniga FS, Wu M, Luthens AK, Gillis J, Zheng W, LaFleur MW, Johnson SB, Morad G, Park EM, Zhou Y, Watowich SS, Wargo JA, Freeman GJ, Kasper DL, Sharpe AH. Park JS, et al. Nature. 2023 May;617(7960):377-385. doi: 10.1038/s41586-023-06026-3. Epub 2023 May 3. Nature. 2023. PMID: 37138075
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, Bordia S, McGuinness D, Cui K, Locker GY, Golan T. Kindler HL, et al. Among authors: park jo. J Clin Oncol. 2022 Dec 1;40(34):3929-3939. doi: 10.1200/JCO.21.01604. Epub 2022 Jul 14. J Clin Oncol. 2022. PMID: 35834777 Clinical Trial.
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, Golan T, Geva R, Borad MJ, Pedersen KS, Park JO, Ramirez RA, Abad DG, Feliu J, Muñoz A, Ponz-Sarvise M, Peled A, Lustig TM, Bohana-Kashtan O, Shaw SM, Sorani E, Chaney M, Kadosh S, Vainstein Haras A, Von Hoff DD, Hidalgo M. Bockorny B, et al. Among authors: park jo. Nat Med. 2020 Jun;26(6):878-885. doi: 10.1038/s41591-020-0880-x. Epub 2020 May 25. Nat Med. 2020. PMID: 32451495 Clinical Trial.
1,442 results